In The Spotlight
DDNews Cancer Research Exclusive
(Photo credit: Stephan Lab / Fred Hutchinson Cancer Research Center)
Biomedical mesh loaded with T cells and implanted on tumors led to tumor clearance in mouse models, Fred Hutchinson team reports
UC San Diego study indicates mutant HRAS is a druggable target, as well as a key oncogene
Tecartus, a one-time CAR T cell treatment for relapsed or refractory mantle cell lymphoma, achieved an 87% response rate in ZUMA-2 trial
Base Genomics raises $11M to develop and commercialize epigenetic technology for early detection of cancer
Gene signature found for poor response to standard chemotherapy in rare uterine cancer
Agilent Technologies Inc.ís PD-L1 IHC 28-8 pharmDx recently received the nod from the U.S. Food and Drug Administration
Adding Optune to chemotherapy more than doubled five-year overall survival rate
A roundup of instrumentation, software and other tools and technology news
Specially designed fusion protein ALKS 4230 could target many solid tumors
Recent happenings on the R&D front to better understand cancer and create oncology therapeutics
by Martin Lachs/Brandon Fletcher
As excitement and investment related to adoptive cell transfer products increases, there are concerns and issues that need to be addressed in terms of long-term follow-up trials

by Sue Cramp, Charles River
In pursuit of new options for treating childhood cancers, a new approach to drug discovery and development may be an answer

by Andrea Toell of Lonza
Andrea Toell of Lonza shares how CAR T cells are transforming immuno-oncology

1000 N West Street, Suite 1200,
Wilmington, Delaware, 19801
Ph: 888-781-0328 |  Fax: 705-528-0270
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.